164
Views
0
CrossRef citations to date
0
Altmetric
Review

Prognostic and Predictive Factors in Patients Treated with Chemotherapy for Advanced Urothelial Cancer: Where Do We Stand?

, , , , , , , , , , , , & show all
Pages 107-119 | Published online: 09 Jan 2015

References

  • Foster CS , RossJS. Pathology of the Urinary Bladder.Saunders, PA, USA, 183–267 (2004).
  • Siegel R , NaishadhamD, JemalA. Cancer statistics 2012. CA Cancer J. Clin.62(1), 10–29, (2012).
  • Kogenivas M , MannetjeAT, CordierSet al. Occupation and bladder cancer. among men in western Europe. Cancer Causes Control14(10), 907–914 (2003).
  • Roth BJ , BajorinDF. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J. Urol.153(3 Pt 2), 894–900 (1995).
  • Von der Maase H , SengelovL, RobertsJTet al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
  • Costantini C , MillardF. Update on chemotherapy in the treatment of urothelial carcinoma. Sci. World J.11, 1981–1994 (2011).
  • Albers P , ParkSI, NiegischGet al. Randomized Phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann. Oncol.22(2), 288–294 (2011).
  • Naiki T , KawaiN, HashimotoYet al. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. Int. J. Clin. Oncol.19(3), 516–522 (2014).
  • Pond GR , BellmuntJ, FougerayRet al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin. Genitourin. Cancer11(4), 495–500 (2013).
  • Dogliotti L , CartenìG, SienaSet al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 trial. Eur. Urol.52(1), 134–141 (2007).
  • Buti S . Does the cetuximab plus paclitaxel combination deserve to be studied in a Phase III trial?J. Clin. Oncol.31(12), 1613–1614 (2013).
  • NIH . ClinicalTrials.gov.https://clinicaltrials.gov
  • Logothetis CJ , DexeusFH, FinnLet al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol.8(6), 1050–1055 (1990).
  • Loehrer PJ Sr , EinhornLH, ElsonPJet al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.10(7), 1066–1073 (1992).
  • Saxman SB , PropertKJ, EinhornLHet al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol.15(7), 2564–2569 (1997).
  • Sengel⊘v L , KambyC, SchouG, von der MaaseH. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer74(1), 123–133 (1994).
  • Sengel⊘v L , NielsenOS, KambyC, von der MaaseH. Platinum analogue combination chemotherapy: cisplatin, carboplatin and methotrexate in patients with metastatic urothelial tract tumors. A Phase II trial with evaluation of prognostic factors. Cancer76(10), 1797–1803 (1995).
  • Bajorin DF , DoddPM, MazumdarMet al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol.17(10), 3173–3181 (1999).
  • Sengel⊘v L , KambyC, GeertesenP, AndersenLJ, von der MaaseH. Predictive factors of response to cispltin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother. Pharmacol.46(5), 357–364 (2000).
  • Sengel⊘v L , KambyC, von der MaaseH. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur. Urol.39(6), 634–642 (2001).
  • Stadler WM , AnnamariaH, von der MaaseHet al. Long-term survival in Phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol. Oncol.7(4), 153–157 (2002).
  • Bellmunt J , AlbanellJ, Paz-AresLet al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a Phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer95(4), 751–757 (2002).
  • Roychowdhury DF , HaydenA, LiepaAM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J. Clin. Oncol.21(4), 673–678 (2003).
  • Bamias A , AravantinosG, DeliveliotisCet al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol.22(2), 220–228 (2004).
  • Bamias A , EfstathiouE, MoulopoulosLAet al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann. Oncol.16(2), 307–313 (2005).
  • Lin CC , HsuCH, HuangCYet al. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology69(3), 479–484 (2007).
  • Jessen C , AgerbaekM, Von Der MaaseH. Predictive factors for response and prognostic factors for long-term urvival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncol.48(3), 411–417 (2009).
  • Matsumura N , NakamuraY, KohjimotoYet al. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer. treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int.108 (2 Pt 2), E110–E116 (2010).
  • De Santis M , BellmuntJ, MeadGet al. Randomized Phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol.30(2), 191–199 (2012).
  • Bellmunt J , von der MaaseH, MeadGMet al. Randomized Phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol.30(10), 1107–1111 (2012).
  • Nakagawa T , HaraT, KawaharaTet al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J. Urol.189(4), 1275–1281 (2013).
  • Taguchi S , NakagawaT, HattoriMet al. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy. Jpn J. Clin. Oncol.43(9), 923–928 (2013).
  • Bellmunt J , ChoueiriTK, FougerayRet al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol.28(11), 1850–1855 (2010).
  • Niegisch G , FimmersR, SienerRet al. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur. Urol.60(5), 1087–1096 (2011).
  • Ikeda M , MatsumotoK, TabataKet al. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J. Clin. Oncol.41(10), 1214–1220 (2011).
  • Lee JL , AhnJH, ParkSHet al. Phase II study of a Cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest. New Drugs30(5), 1984–1990 (2012).
  • Krajewski KM , FougerayR, BellmuntJet al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur. J. Cancer48(10), 1495–1502 (2012).
  • Choueiri TK , RossRW, JacobusSet al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J. Clin. Oncol.30(5), 507–512 (2012).
  • Ko YJ , CanilCM, MukherjeeSDet al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, Phase 2 study. Lancet Oncol.14(8), 769–776 (2013).
  • Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
  • Bellmunt J , ThéodoreC, DemkovTet al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
  • Vaughn DJ , SrinivasS, StadlerWMet al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial cancer: results of a large Phase II study. Cancer115(18), 4110–4117 (2009).
  • Olaussen KA , DunantA, FouretPet al. DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med.355(10), 983–991 (2006).
  • Bellmunt J , Paz-AresL, CuelloMet al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer. patients receiving cisplatin-based chemotherapy. Ann. Oncol.18(3), 522–528 (2007).
  • Hoffmann AC , WildP, LeichtCet al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer. receiving adjuvant chemotherapy. Neoplasia12(8), 628–636 (2010).
  • Kawashima A , TakayamaH, KawamuraNet al. Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncol. Lett.4(1), 15–21 (2012).
  • Krüger S , WeitschG, BüttnerHet al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int. J. Oncol.21(5), 981–987 (2002).
  • Miyamoto H , KubotaY, NoguchiSet al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology55(5), 679–683. (2000)
  • van Oers JM , ZwarthoffEC, RehmanIet al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur. Urol.55(3), 650–657 (2009).
  • Tomlinson DC , LamontFR, ShnyderSDet al. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res.69(11), 4613–4620. (2009).
  • Tomlinson DC , KnowlesMA. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am. J. Pathol.77(5), 2379–2386. (2010).
  • Kopparapu PK , BoorjianSA, RobinsonBDet al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res.33(6), 2381–2390 (2013).
  • Inoue K , SlatonJW, KimSJet al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res.60(8), 2290–2299 (2000).
  • Garg M , KanojiaD, SethAet al. Heat-shock protein 70–2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur. J. Cancer46(1), 207–215. (2010).
  • Kamada M , SoA, MuramakiMet al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer. cells. Mol. Cancer Ther.6(1), 299–308. (2007).
  • Hansel DE , PlattE, OrloffMet al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am. J. Pathol.176(6), 3062–3072 (2010).
  • Iyer G , HanrahanAJ, MilowskyMIet al. Genome sequencing identifies a basis for everolimus sensitivity. Science338(6104), 221 (2012).
  • Zaharieva B , SimonR, RuizCet al. High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int. J. Cancer117(6), 952–956. (2005).
  • Choi JW , KimY, LeeJH, KimYS. Expression of β-tubulin isotypes in urothelial carcinoma of the bladder. World J. Urol.32(2), 347–352 (2014).
  • Gallagher DJ , MilowskyMI, IshillNet al. Detection of circulating tumor cells in patients with urothelial cancer. Ann. Oncol.20(2), 305–308. (2009).
  • Ioachim E , MichaelMC, SalmasMet al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer6, 140 (2006).
  • Furuta T , UedaT, AuneGet al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res.62(17), 4899–4902 (2002).
  • Park CH , BesshoT, MatsunagaT, SancarA. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J. Biol. Chem.270(39), 22657–22660 (1995).
  • Mu D , HsuDS, SancarA. Reaction mechanism of human DNA repair excision nuclease. J. Biol. Chem.271(14), 8285–8294 (1996).
  • Matsunaga T , MuD, ParkCH, ReardonJT, SancarA. Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J. Biol. Chem.270(35), 20862–20869 (1995).
  • Shirota Y , StoehlmacherJ, BrabenderJet al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol.19(23), 4298–4304 (2001).
  • Metzger R , LeichmanCG, DanenbergKDet al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol.16(1), 309–316 (1998).
  • Dabholkar M , VionnetJ, Bostick-BrutonF, YuJJ, ReedE. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum based chemotherapy. J. Clin. Invest.94(2), 703–708 (1994).
  • Joshi MB , ShirotaY, DanenbergKDet al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res.11(6), 2215–2221 (2005).
  • Sun JM , AhnMJ, ParkMJet al. Expression of excision repair cross-complementation group 1 as a predictive marker for nasopharyngeal cancer trated with concurrent chemoradiotherapy. Int. J. Oncol. Biol. Phys.80(3), 655–660 (2011).
  • Usanova S , Piée-StaffaA, SiedUet al. Cisplatin sensitivity of testis tumour cells due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol. Cancer9, 248 (2010).
  • Kawashima A , TakayamaH, TsujimuraA. A review of ERCC1 gene in bladder cancer: implications for carcinogenesis and resistance to chemoradiotherapy. Adv. Urol.2012, 812398 (2012).
  • Kawashima A , NakayamaM, KakutaYet al. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin. Cancer Res.17(8), 2561–2569 (2011).
  • Brabletz TA , JungA, ReuSet al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor microenvironment. Proc. Natl Acad. Sci. USA98(18), 10356–10361 (2001).
  • Nakajima S , DoiR, ToyodaEet al. N-cadherin expression and epithelial–mesenchymal transition in pancreatic carcinoma. Clin. Cancer Res.10(12 Pt 1), 4125–4133 (2004).
  • McConkey DJ , ChoiW, MarquisLet al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev.28(3–4), 335–344 (2009).
  • Rieger-Christ KM , NgL, HanleyRSet al. Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br. J. Cancer92(12), 2153–2159 (2005).
  • Gee J , GreatheadP, LittleAFet al. Aberrant cadherin expression in bladder carcinoma cells. Mol. Urol.2(2), 73–81 (1998).
  • Hsu DSS , LanHY, HuangCHet al. Regulation of excision repair cross-complementation group 1 by snail contribuites to cisplatin resistance in head and neck cancer. Clin. Cancer Res.16(18), 4561–4571 (2010).
  • Mackey JR , ManiRS, SelnerMet al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res.58(19), 4349–4357 (1998).
  • Achiwa H , OguriT, SatoS, MaedaH, NiimiT, UedaR. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci.95(9), 753–757 (2004).
  • Spratlin J , SanghaR, GlubrechtDet al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res.10(20), 6956–6961 (2004).
  • Farré X , Guillén-GómezE, SánchezLet al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int. J. Cancer112(6), 959–966 (2004).
  • Mey V , GiovannettiE, De BraudFet al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer. patients. Br. J. Cancer95(3), 289–297 (2006).
  • Sève P , DumontetC. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?Lancet Oncol.9(2), 168–175 (2008).
  • Esrig D , SpruckCH3rd, NicholsPWet al. P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol.143(5), 1389–1397 (1993).
  • Esrig D , ElmajianD, GroshenSet al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med.331(19), 1259–1264 (1994).
  • Sarkis AS , DalbagniG, Cordon-CardoCet al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Inst.85(1), 53–59 (1993).
  • Lipponen PK . Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer. and its prognostic value. Int. J. Cancer53(3), 365–370 (1993).
  • Stadler WM , LernerSP, GroshenSet al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol.29(25), 3443–3449 (2011).
  • Sarkis AS , BajorinDF, ReuterVEet al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol.13(6), 1384–1390 (1995).
  • Yancik R , RiesLA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol. Oncol. Clin. North Am.14(1), 17–21 (2000).
  • Balducci L , ExtermannM. Management of cancer in the older person: a practical approach. Oncologist5(3), 224–237 (2000).
  • Audisio RA , RameshH, LongoWEet al. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist10(4), 262–268 (2005).
  • Resorlu B , BedukY, BaltaciSet al. The prognostic significante of advanced age in patient with bladder cancer treated with radical cystectomy. BJU Int.103(4), 480–483 (2008).
  • Bamias A , EfstathuousE, MoulopoulosLAet al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann. Oncol.16(2), 307–313 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.